FDA research on drug advertising has found that “people may be overly optimistic when they see ads with claims about overall response rate [ORR] and progression-free survival [PFS] without a disclosure stating that the drug has not yet been shown to extend life.” FDA Office of Prescription Drug Promotion (OPDP) researchers concluded that “disclosures could help reduce the ext... Read More